[{"orgOrder":0,"company":"Orexia Therapeutics","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Spin-Off Company Orexia Therapeutics Merged Into Newly Created Centessa Pharmaceuticals","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Orexia Therapeutics"},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enalare Therapeutics Receives Rare Pediatric Disease Designation for Lead Compound ENA-001 for the Treatment of Apnea of Prematurity.","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Enalare Therapeutics"},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KemPharm Completes KP1077 Pre-IND Meeting Process with FDA","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"KemPharm"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"RespireRx Pharmaceuticals"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tris Pharma Announces Development of a Very Low Sodium and Once-Nightly Oxybate Formulation","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Tris Pharma Inc"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Enalare Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals and Enalare Therapeutics Announce FDA Orphan Drug Designation for ENA-001 for the Treatment of Apnea of Prematurity, a New Chemical Entity Being Developed as an Agnostic Respiratory Stimulant","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Eagle Pharmaceuticals"},{"orgOrder":0,"company":"Enalare Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enalare Therapeutics Receives Orphan Drug Designation From the U.S. FDA on ENA-001 for the Treatment of Apnea of Prematurity (AoP)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Enalare Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PsychoGenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"F. Hoffmann-La Roche"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Aexon Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"NLS Pharmaceutics"},{"orgOrder":0,"company":"Aexon Labs","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Undisclosed","graph2":"Aexon Labs"},{"orgOrder":0,"company":"Bioprojet Pharma","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","amount":"$393.0 million","upfrontCash":"$25.5 million","newsHeadline":"Harmony Biosciences Announces Exclusive Agreement to Develop and Commercialize Tpm-1116, a Highly Potent and Selective Oral Orexin-2 Receptor Agonist","therapeuticArea":"Sleep","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Bioprojet Pharma"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Through the Licensing Agreement, Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders.
The agreement grants NLS global rights to next-generation, oral, OX1R/OX2R agonists, including AEX-2, tailored to target narcolepsy, idiopathic hypersomnia, Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, all of which involve cathepsins.
Under the agreement, Roche obtains global development, manufacturing, and commercialization rights to RO7117997, an IND-ready ENT1 inhibitor discovered using the PsychoGenics’ AI-enabled phenotypic screening platforms.
Under the agreement, NLS may acquire development and commercialization rights to Aexon Labs' dual orexin receptor agonists platform for the treatment of narcolepsy and idiopathic hypersomnia, as well as neuro-degenerative disorders.
ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The compound has a novel mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body.
Enalare's lead compound, ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The compound has a novel mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body.
In a human clinical study, Tris established about 100% bioavailability for one dose of its formulation against two doses of XYREM at 4.5 gm each, equivalent to the 9.0 gm maximum dose of sodium oxybate.
Provisional patent application describing novel lipid based formulation technology (LFT) that may be used to improve the solubility and bioavailability of poorly soluble drugs particularly cannabinoids Dronabinol that is formulated as a sesame oil emulsion.
The successful completion of the pre-IND meeting process with the FDA for KP1077 affirms company's plan to submit the IND application by mid-year 2022 and to initiate a Phase 2 trial of KP1077 for Idiopathic Hypersomnia.
Rare Pediatric Disease Designation received for ENA-001, a unique agnostic respiratory stimulant has the potential to significantly improve the standard of care for neonates experiencing life-threatening and debilitating respiratory conditions.